Latest Spectrum Pharmaceuticals (SPPI) Headlines
Post# of 41
Posted On: 03/13/2014 2:15:00 PM
Latest Spectrum Pharmaceuticals (SPPI) Headlines
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The Cancer Monoclonal Antibodies Market is Estimated at US$ 24 Billion, and is expected to Grow to Around US$ 34 Billion by 2017
M2 - Tue Mar 11, 10:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghw3bj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" report to their offering. Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies. Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs. In this report, the authors have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs. Through this pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs. Companies Mentioned: - Amgen - Bristol-Myers Squibb - Eli Lilly - Genmab - GlaxoSmithKline - Roche - Seattle Genetics - Spectrum Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/gh...monoclonal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Spectrum Pharma Posts Lower Y/Y Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:00AM CST
Spectrum Pharma reported fourth quarter 2013 earnings of 5 cents per share, well below the year-ago earnings of 29 cents per share.
Spectrum Pharmaceuticals to Present Corporate Update at the 26th Annual ROTH Conference in Laguna Niguel on March 11th
Business Wire - Fri Mar 07, 6:00AM CST
Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the 26th Annual ROTH Conference being held at The Ritz-Carlton Hotel in Laguna Niguel, California. The Company presentation is on Tuesday, March 11, 2014, at 11:00 AM PT.
Spectrum Pharmaceuticals Reports Fourth and Full Year 2013 Financial Results
Business Wire - Thu Mar 06, 3:00PM CST
--Q4 Non-GAAP diluted EPS was $0.05, and GAAP basic and diluted EPS was ($0.63); the difference is primarily due to non-cash charges.
Spectrum Pharmaceuticals Announces Fourth Quarter 2013 Financial Results Teleconference and Webcast
Business Wire - Thu Feb 27, 3:06PM CST
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the fourth quarter 2013 financial results, provide an update on the Company's business, and discuss expectations for the future.
Investors are betting against Spectrum Pharmaceuticals (SPPI), Should You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:25AM CST
Investors are betting against Spectrum Pharmaceuticals (SPPI), Should You?
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market in the G8 Countries to 2020
M2 - Tue Feb 25, 10:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/gfrpmb/acute) has announced the addition of the "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)" report to their offering. The acute lymphocytic/lymphoblastic leukemia therapeutics market has growth potential with increasing incidence rate of the disease across the globe. The incidence of acute lymphocytic/lymphoblastic leukemia is higher in children from 0 to 14 years than in those aged 15 years and above. However, acute lymphocytic/lymphoblastic leukemia may also occur in adults. The acute lymphocytic/lymphoblastic leukemia market is segmented into two types - childhood acute lymphocytic/lymphoblastic leukemia and adult acute lymphocytic/lymphoblastic leukemia. The acute lymphocytic/lymphoblastic leukemia therapeutics market primarily covers regimens and drugs (patented, off-patent, and pipeline). The growing acute lymphocytic/lymphoblastic leukemia incidence rate is an impetus for the growth of the market. This market is expected to grow at a CAGR of 4.0% from 2015 to 2020. In 2012, the overall ALL therapeutics market was dominated by Linker regimen, Hyper-CVAD regimen, and Nucleoside metabolic inhibitors treatments. However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.). In contrast to the growth of the market, the cost of therapies is majorly restraining the acute lymphocytic/lymphoblastic leukemia therapeutics market. In addition, patent expirations of some of the existing drugs in the market are also expected to limit the market growth during 2013 to 2020. Market players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to November 2013. Scope of the Report Existing Regimens/Drugs - Hyper-CVAD Regimen - CALGB 8811 Regimen - Linker Regimen - Nucleoside Metabolic Inhibitors (Clolar and Nelarabine) - Oncaspar Pipeline Drugs (Phase III) - Graspa - Marqibo - Inotuzumab Ozogamicin Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Acute Lymphocytic Leukemia Market Dynamics 5 Leukemia Product Market 6 Acute Lymphocytic Leukemia Pipeline Molecules (Phase III) 7 Geographic Analysis 8 Company Profiles - Erytech Pharma - Genzyme Corporation - Glaxosmithkline Plc - Pfizer Inc - Sigma-Tau Pharmaceuticals, Inc - Talon Therapeutics, Inc (Spectrum Pharmaceuticals, Inc) For more information visit http://www.researchandmarkets.com/research/gfrpmb/acute
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Bone Marrow Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8glf8/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Scope - A snapshot of the global therapeutic scenario for Bone Marrow Transplantation. - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Bone Marrow Transplantation Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Bone Marrow Transplantation - Therapeutics Assessment Drug Profiles Allogeneic MPC For Bone Marrow Transplantation - Drug Profile melphalan - Drug Profile TM-400 - Drug Profile PLX-BMP - Drug Profile CBLB-612 - Drug Profile CBLB-612 - Drug Profile Perforin Inhibitor - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Mesoblast Limited Cleveland BioLabs, Inc. Pluristem Therapeutics Inc. Spectrum Pharmaceuticals, Inc. TikoMed AB For more information visit http://www.researchandmarkets.com/research/f8...one_marrow About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
Dan Carroll, The Motley Fool - Motley Fool - Sun Feb 23, 3:53PM CST
No industry embraces the boom-or-bust potential of the stock market like the biotech industry. Under-the-radar stocks can produce huge returns for investors from successful drug approvals, milestone achievements, and other events. But which stocks...
Biotech Stock 'Hate' Mailbag: Readers Riot Over Galena, Prana
at The Street - Thu Feb 20, 9:56AM CST
I've received so much hate email and tweets over the past week, enough to fill a special edition of the Mailbag.
Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
M2 - Mon Feb 17, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/xx9pc7/competitor) has announced the addition of the Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors report to their offering. The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world's commercially most successful antibodies (2013 sales of over US$ 7.7 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Sales of rituximab for treatment of rheumatoid athritis makes out 17.1% of total Rituxan (US) / MabThera (EU) sales.Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies as a measure to protect against emerging rituximab biosimilars. In fact, second generation anti-CD20 antibody Gazyva has already been approved and launched in ist first indication. The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in off-patent countries, but also in phase III studies in Western regulated markets. The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Key Topics Covered: 1. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors Marketed CD20 Antibodies & Sales - Rituxan/MabThera Pipeline & Sales - Arzerra Pipeline & Sales - Gazyva Pipeline & Sales - Bexxar & Zevalin Pipeline & Sales Biosuperior CD20 Antibodies Biosimilar CD20 Antibodies - Rituxan/MabThera (rituximab) Biosimilars - Arzerra (ofatumumab) Biosimilars 2. Corporate CD20 Antibody Biosimilar & Biobetter Pipelines Companies Mentioned: - Actavis (Watson Pharmaceuticals) - Alopexx Oncology - Amgen - Aprogen - Competitor Analysis - Innovent Biologics - Intas Pharmaceuticals - Lentigen - LG Life Sciences - Libbs Farmaceutica - Mabxience - Mentrik Biotech - Merck - Molecular Templates - Natco Pharma - Nichi-Iko Pharmaceutical - Oncobiologics - PanGenerika - PanPharmaceuticals USA - Pfizer - PharmaPraxis - PlantForm - Probiomed - rEVO Biologics - Roche - Sandoz (Novartis) - Shanghai CP Guojian Pharmaceutical Co - Shanghai Henliu Biopharmaceuticals - Spectrum Pharmaceuticals - STADA Arzneimittel 68 - TG Therapeutics - Therapeutics Protein International (TPI) - TRION Pharma - Vaccinex - Valor Biotherapeutics - Viropro - Zhejiang Huahai Pharmaceutical Co For more information visit http://www.researchandmarkets.com/research/xx9pc7/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Biotech Stock Roundup: Gilead's Sovaldi Impresses, EU Nod for Biogen's Tecfidera - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 12, 7:27AM CST
Last week saw companies like Gilead coming out with strong results. There were also a few regulatory updates.
Is Spectrum Pharmaceuticals, Inc. Blazing the Comeback Trail?
George Budwell, The Motley Fool - Motley Fool - Mon Feb 10, 7:30AM CST
Wall Street isn't a big fan of Spectrum Pharmaceuticals . Presently, 23% of the shares are being sold short and the company's stock has lost over a third of its value in the last year alone. Spectrum's fall during a time when the entire biotech...
FDA to Review Spectrum Pharma' Beleodaq - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 4:00PM CST
The FDA accepted the NDA for Spectrum Pharma's Beleodaq.
Spectrum rises as FDA starts lymphoma drug review
AP - Thu Feb 06, 1:18PM CST
NEW YORK (AP) — Shares of Spectrum Pharmaceuticals rose Thursday after the company said the Food and Drug Administration will conduct a fast review of its lymphoma drug Beleodaq.
OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017
M2 - Thu Feb 06, 11:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/lkw2vq/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017" report to their offering. The bladder cancer market in the 6MM to grow modestly from $239.3m in 2012 to $297.5m in 2017, at a CAGR of 4%. Despite the Launch of Spectrum Pharmaceuticals' EOquin, Nominal Growth in US and EU Bladder Cancer Market Is Expected from 2012 to 2017 The authors estimates the bladder cancer market in the US and 5EU (France, Germany, Italy, Spain, and UK) in 2012 to be valued at $239.3m. This market is defined as the sales of branded drugs, including Valstar (US only) and Javlor (Europe only), and major generics regimens across both markets. Predominantly due to the higher price of drugs, the majority of sales were generated in the US market, $139.4m (58%), with EU sales estimated to be $99.8m (42%). By the end of the study period in 2017, The authors forecasts global sales in the bladder cancer market to increase to $297.5m, at a compound annual growth rate (CAGR) of 4%. The majority of sales at this point will still come from the US, with $181.1m (61%), with its market share increasing marginally from 58% in 2012 to 61% by the end of the forecast period. Overall, The authors expects an increase in market size primarily due to a forecast increase in number of incident cases across the study period in the 6MM and the entrance of EOquin into the market during the forecast period. The emergence of Spectrum Pharmaceuticals' EOquin, the only product in the pipeline to enter the market during the forecast period, will also have a small incremental effect on the bladder cancer market. Global sales for EOquin will account for $13.2m in its launch year, 2016, and $26.1m in 2017, accounting for 8.8% of sales in that year. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Epidemiology 4.1 Disease Background 4.2 Risk Factors and Comorbidities 4.3 Global Trends 4.4 Forecast Methodology 4.5 Epidemiological Forecast for Bladder Cancer (2012-2022) 4.6 Discussion 5 Current Treatment Options 5.1 Overview 5.2 Product Profiles - Major Brands 6 Unmet Needs Assessment and Opportunity Analysis 6.1 Overview 6.2 Unmet Needs Analysis 6.3 Opportunity Analysis 7 R&D Strategies 7.1 Overview 7.2 Clinical Trial Design 8 Pipeline Assessment 8.1 Overview 8.2 Promising Drugs in Clinical Development 8.3 Innovative Early-Stage Approaches 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/lk...ityanalyze
Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Beleodaq(TM) (belinostat) for Injection, a novel pan-HDAC inhibitor
Business Wire - Thu Feb 06, 6:00AM CST
--FDA decision date based on PDUFA set for August 9, 2014
DebtX: CMBS Loan Prices Rise 4% In 2013
PR Newswire - Thu Jan 30, 8:00AM CST
DebtX, the largest marketplace for loans, said today that Commercial Real Estate (CRE) loan prices in the secondary market held steady in December but increased modestly for 2013 overall.
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The Cancer Monoclonal Antibodies Market is Estimated at US$ 24 Billion, and is expected to Grow to Around US$ 34 Billion by 2017
M2 - Tue Mar 11, 10:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghw3bj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" report to their offering. Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies. Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs. In this report, the authors have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs. Through this pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs. Companies Mentioned: - Amgen - Bristol-Myers Squibb - Eli Lilly - Genmab - GlaxoSmithKline - Roche - Seattle Genetics - Spectrum Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/gh...monoclonal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Spectrum Pharma Posts Lower Y/Y Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:00AM CST
Spectrum Pharma reported fourth quarter 2013 earnings of 5 cents per share, well below the year-ago earnings of 29 cents per share.
Spectrum Pharmaceuticals to Present Corporate Update at the 26th Annual ROTH Conference in Laguna Niguel on March 11th
Business Wire - Fri Mar 07, 6:00AM CST
Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the 26th Annual ROTH Conference being held at The Ritz-Carlton Hotel in Laguna Niguel, California. The Company presentation is on Tuesday, March 11, 2014, at 11:00 AM PT.
Spectrum Pharmaceuticals Reports Fourth and Full Year 2013 Financial Results
Business Wire - Thu Mar 06, 3:00PM CST
--Q4 Non-GAAP diluted EPS was $0.05, and GAAP basic and diluted EPS was ($0.63); the difference is primarily due to non-cash charges.
Spectrum Pharmaceuticals Announces Fourth Quarter 2013 Financial Results Teleconference and Webcast
Business Wire - Thu Feb 27, 3:06PM CST
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the fourth quarter 2013 financial results, provide an update on the Company's business, and discuss expectations for the future.
Investors are betting against Spectrum Pharmaceuticals (SPPI), Should You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:25AM CST
Investors are betting against Spectrum Pharmaceuticals (SPPI), Should You?
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market in the G8 Countries to 2020
M2 - Tue Feb 25, 10:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/gfrpmb/acute) has announced the addition of the "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)" report to their offering. The acute lymphocytic/lymphoblastic leukemia therapeutics market has growth potential with increasing incidence rate of the disease across the globe. The incidence of acute lymphocytic/lymphoblastic leukemia is higher in children from 0 to 14 years than in those aged 15 years and above. However, acute lymphocytic/lymphoblastic leukemia may also occur in adults. The acute lymphocytic/lymphoblastic leukemia market is segmented into two types - childhood acute lymphocytic/lymphoblastic leukemia and adult acute lymphocytic/lymphoblastic leukemia. The acute lymphocytic/lymphoblastic leukemia therapeutics market primarily covers regimens and drugs (patented, off-patent, and pipeline). The growing acute lymphocytic/lymphoblastic leukemia incidence rate is an impetus for the growth of the market. This market is expected to grow at a CAGR of 4.0% from 2015 to 2020. In 2012, the overall ALL therapeutics market was dominated by Linker regimen, Hyper-CVAD regimen, and Nucleoside metabolic inhibitors treatments. However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.). In contrast to the growth of the market, the cost of therapies is majorly restraining the acute lymphocytic/lymphoblastic leukemia therapeutics market. In addition, patent expirations of some of the existing drugs in the market are also expected to limit the market growth during 2013 to 2020. Market players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to November 2013. Scope of the Report Existing Regimens/Drugs - Hyper-CVAD Regimen - CALGB 8811 Regimen - Linker Regimen - Nucleoside Metabolic Inhibitors (Clolar and Nelarabine) - Oncaspar Pipeline Drugs (Phase III) - Graspa - Marqibo - Inotuzumab Ozogamicin Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Acute Lymphocytic Leukemia Market Dynamics 5 Leukemia Product Market 6 Acute Lymphocytic Leukemia Pipeline Molecules (Phase III) 7 Geographic Analysis 8 Company Profiles - Erytech Pharma - Genzyme Corporation - Glaxosmithkline Plc - Pfizer Inc - Sigma-Tau Pharmaceuticals, Inc - Talon Therapeutics, Inc (Spectrum Pharmaceuticals, Inc) For more information visit http://www.researchandmarkets.com/research/gfrpmb/acute
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Bone Marrow Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8glf8/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Scope - A snapshot of the global therapeutic scenario for Bone Marrow Transplantation. - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Bone Marrow Transplantation Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Bone Marrow Transplantation - Therapeutics Assessment Drug Profiles Allogeneic MPC For Bone Marrow Transplantation - Drug Profile melphalan - Drug Profile TM-400 - Drug Profile PLX-BMP - Drug Profile CBLB-612 - Drug Profile CBLB-612 - Drug Profile Perforin Inhibitor - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Mesoblast Limited Cleveland BioLabs, Inc. Pluristem Therapeutics Inc. Spectrum Pharmaceuticals, Inc. TikoMed AB For more information visit http://www.researchandmarkets.com/research/f8...one_marrow About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
Dan Carroll, The Motley Fool - Motley Fool - Sun Feb 23, 3:53PM CST
No industry embraces the boom-or-bust potential of the stock market like the biotech industry. Under-the-radar stocks can produce huge returns for investors from successful drug approvals, milestone achievements, and other events. But which stocks...
Biotech Stock 'Hate' Mailbag: Readers Riot Over Galena, Prana
at The Street - Thu Feb 20, 9:56AM CST
I've received so much hate email and tweets over the past week, enough to fill a special edition of the Mailbag.
Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
M2 - Mon Feb 17, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/xx9pc7/competitor) has announced the addition of the Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors report to their offering. The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world's commercially most successful antibodies (2013 sales of over US$ 7.7 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Sales of rituximab for treatment of rheumatoid athritis makes out 17.1% of total Rituxan (US) / MabThera (EU) sales.Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies as a measure to protect against emerging rituximab biosimilars. In fact, second generation anti-CD20 antibody Gazyva has already been approved and launched in ist first indication. The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in off-patent countries, but also in phase III studies in Western regulated markets. The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Key Topics Covered: 1. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors Marketed CD20 Antibodies & Sales - Rituxan/MabThera Pipeline & Sales - Arzerra Pipeline & Sales - Gazyva Pipeline & Sales - Bexxar & Zevalin Pipeline & Sales Biosuperior CD20 Antibodies Biosimilar CD20 Antibodies - Rituxan/MabThera (rituximab) Biosimilars - Arzerra (ofatumumab) Biosimilars 2. Corporate CD20 Antibody Biosimilar & Biobetter Pipelines Companies Mentioned: - Actavis (Watson Pharmaceuticals) - Alopexx Oncology - Amgen - Aprogen - Competitor Analysis - Innovent Biologics - Intas Pharmaceuticals - Lentigen - LG Life Sciences - Libbs Farmaceutica - Mabxience - Mentrik Biotech - Merck - Molecular Templates - Natco Pharma - Nichi-Iko Pharmaceutical - Oncobiologics - PanGenerika - PanPharmaceuticals USA - Pfizer - PharmaPraxis - PlantForm - Probiomed - rEVO Biologics - Roche - Sandoz (Novartis) - Shanghai CP Guojian Pharmaceutical Co - Shanghai Henliu Biopharmaceuticals - Spectrum Pharmaceuticals - STADA Arzneimittel 68 - TG Therapeutics - Therapeutics Protein International (TPI) - TRION Pharma - Vaccinex - Valor Biotherapeutics - Viropro - Zhejiang Huahai Pharmaceutical Co For more information visit http://www.researchandmarkets.com/research/xx9pc7/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Biotech Stock Roundup: Gilead's Sovaldi Impresses, EU Nod for Biogen's Tecfidera - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 12, 7:27AM CST
Last week saw companies like Gilead coming out with strong results. There were also a few regulatory updates.
Is Spectrum Pharmaceuticals, Inc. Blazing the Comeback Trail?
George Budwell, The Motley Fool - Motley Fool - Mon Feb 10, 7:30AM CST
Wall Street isn't a big fan of Spectrum Pharmaceuticals . Presently, 23% of the shares are being sold short and the company's stock has lost over a third of its value in the last year alone. Spectrum's fall during a time when the entire biotech...
FDA to Review Spectrum Pharma' Beleodaq - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 4:00PM CST
The FDA accepted the NDA for Spectrum Pharma's Beleodaq.
Spectrum rises as FDA starts lymphoma drug review
AP - Thu Feb 06, 1:18PM CST
NEW YORK (AP) — Shares of Spectrum Pharmaceuticals rose Thursday after the company said the Food and Drug Administration will conduct a fast review of its lymphoma drug Beleodaq.
OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017
M2 - Thu Feb 06, 11:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/lkw2vq/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017" report to their offering. The bladder cancer market in the 6MM to grow modestly from $239.3m in 2012 to $297.5m in 2017, at a CAGR of 4%. Despite the Launch of Spectrum Pharmaceuticals' EOquin, Nominal Growth in US and EU Bladder Cancer Market Is Expected from 2012 to 2017 The authors estimates the bladder cancer market in the US and 5EU (France, Germany, Italy, Spain, and UK) in 2012 to be valued at $239.3m. This market is defined as the sales of branded drugs, including Valstar (US only) and Javlor (Europe only), and major generics regimens across both markets. Predominantly due to the higher price of drugs, the majority of sales were generated in the US market, $139.4m (58%), with EU sales estimated to be $99.8m (42%). By the end of the study period in 2017, The authors forecasts global sales in the bladder cancer market to increase to $297.5m, at a compound annual growth rate (CAGR) of 4%. The majority of sales at this point will still come from the US, with $181.1m (61%), with its market share increasing marginally from 58% in 2012 to 61% by the end of the forecast period. Overall, The authors expects an increase in market size primarily due to a forecast increase in number of incident cases across the study period in the 6MM and the entrance of EOquin into the market during the forecast period. The emergence of Spectrum Pharmaceuticals' EOquin, the only product in the pipeline to enter the market during the forecast period, will also have a small incremental effect on the bladder cancer market. Global sales for EOquin will account for $13.2m in its launch year, 2016, and $26.1m in 2017, accounting for 8.8% of sales in that year. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Epidemiology 4.1 Disease Background 4.2 Risk Factors and Comorbidities 4.3 Global Trends 4.4 Forecast Methodology 4.5 Epidemiological Forecast for Bladder Cancer (2012-2022) 4.6 Discussion 5 Current Treatment Options 5.1 Overview 5.2 Product Profiles - Major Brands 6 Unmet Needs Assessment and Opportunity Analysis 6.1 Overview 6.2 Unmet Needs Analysis 6.3 Opportunity Analysis 7 R&D Strategies 7.1 Overview 7.2 Clinical Trial Design 8 Pipeline Assessment 8.1 Overview 8.2 Promising Drugs in Clinical Development 8.3 Innovative Early-Stage Approaches 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/lk...ityanalyze
Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Beleodaq(TM) (belinostat) for Injection, a novel pan-HDAC inhibitor
Business Wire - Thu Feb 06, 6:00AM CST
--FDA decision date based on PDUFA set for August 9, 2014
DebtX: CMBS Loan Prices Rise 4% In 2013
PR Newswire - Thu Jan 30, 8:00AM CST
DebtX, the largest marketplace for loans, said today that Commercial Real Estate (CRE) loan prices in the secondary market held steady in December but increased modestly for 2013 overall.
(0)
(0)Spectrum Pharmaceuticals (SPPI) Stock Research Links
Scroll down for more posts ▼